Overview

A Study to Evaluate the Effects of YM872 on Brain Function and Disability When Administered in Combination With Alteplase (Tissue Plasminogen Activator)

Status:
Completed

Trial end date:
2003-01-01

Target enrollment:

Participant gender:

Summary

The purpose of this study is to determine if YM872 in combination with t-PA can reduce disability and brain damage from stroke. YM872 or placebo will be given as a continuous intravenous (iv) infusion for 24 hours. It is important that the study medication, YM872 or placebo, is administered prior to the completion of the t-PA administration. The clinical effects of YM872 in addition to t-PA will be determined by assessing neurological function and disability scores at follow up visits through Day 90 of the study.

Phase:

Phase 2

Details

Lead Sponsor:

Astellas Pharma Inc

Collaborator:

Astellas Pharma US, Inc.

Treatments:

Plasminogen
Tissue Plasminogen Activator